Edwards Lifesciences Corp (NYSE:EW) disclosed that Daniel J. Lippis, Corporate Vice President of Transcatheter Aortic Valve Replacement (TAVR), sold shares valued at $64,530 on November 10, 2026, according to a recent regulatory filing. The transaction involved both the exercise of employee stock options and the subsequent sale of common stock.
Lippis disposed of 619 common shares at a price of $104.25 per share, generating total proceeds of $64,530. The sale price is closely aligned with the stock's current trading level of $104.01, which sits near its 52-week high of $105.37. According to analysis, Edwards Lifesciences appears overvalued at current levels, with the stock delivering a robust 35% return over the past six months.
Prior to the sale, Lippis acquired 619 common shares by exercising employee stock options at a price of $72.68 per share, totaling $44,988. These options were exercisable as of May 7, 2021, and are set to expire on May 6, 2027.
Both the option exercise and the subsequent sale were executed under a Rule 10b5-1 trading plan, which Lippis adopted on February 13, 2026. Following these transactions, Lippis directly holds 40,033.9103 shares of Edwards Lifesciences common stock.
In other recent developments, Edwards Lifesciences reported impressive third-quarter results, with sales reaching $1.716 billion, marking an 11.2% growth in constant currency. The company's adjusted earnings per share were $0.80, surpassing the guidance range and consensus expectations. This performance led Wells Fargo to raise its price target for the company to $113, while maintaining an Overweight rating. Similarly, Mizuho increased its price target to $120, citing a $38 million earnings beat due to strong performance in transcatheter aortic valve replacement and other therapies. Truist Securities also raised its price target to $118, highlighting the 8.8% growth in the transcatheter aortic valve replacement segment. TD Cowen reiterated a Buy rating with a $117 price target, acknowledging Edwards Lifesciences' strong third-quarter performance. The firm also emphasized the company's position in the transcatheter mitral and tricuspid therapies market. These developments reflect a positive outlook from analysts, who have adjusted their price targets in response to the company's robust financial performance.